FDA rejects Coherus' biosimilar for Amgen's Neulasta
Coherus BioSciences Inc said on Monday the U.S. Food and Drug Administration (FDA) did not approve its biosimilar version of Amgen Inc's blockbuster treatment, Neulasta, which fights infections in cancer patients. The FDA's response comes as Amgen expects biosimilar competition for Neulasta by the fourth quarter of 2017.
Royal Industry News
Top news stories about the automotive industry. And, news from around the world.